Entrada Therapeutics (TRDA) Equity Ratio: 2022-2025
Historic Equity Ratio for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to 0.83.
- Entrada Therapeutics' Equity Ratio rose 8.33% to 0.83 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.83, marking a year-over-year increase of 8.33%. This contributed to the annual value of 0.81 for FY2024, which is 57.68% up from last year.
- Entrada Therapeutics' Equity Ratio amounted to 0.83 in Q3 2025, which was down 2.42% from 0.85 recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' Equity Ratio ranged from a high of 0.88 in Q1 2022 and a low of 0.42 during Q2 2023.
- In the last 3 years, Entrada Therapeutics' Equity Ratio had a median value of 0.74 in 2024 and averaged 0.66.
- Per our database at Business Quant, Entrada Therapeutics' Equity Ratio crashed by 51.59% in 2023 and then spiked by 76.37% in 2024.
- Quarterly analysis of 4 years shows Entrada Therapeutics' Equity Ratio stood at 0.84 in 2022, then slumped by 38.75% to 0.52 in 2023, then surged by 57.68% to 0.81 in 2024, then increased by 8.33% to 0.83 in 2025.
- Its Equity Ratio stands at 0.83 for Q3 2025, versus 0.85 for Q2 2025 and 0.86 for Q1 2025.